Company news
Ribomic, Inc. (TSE:4591) news
Ribomic, Inc. news releases on 6ix. Latest, Oct 6, 2026: RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol…
Press releases & updates
RIBOMIC Announces Interim Report on the Phase 2 Long-Term Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
October 6, 2026
[Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study
September 29, 2026
RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
August 24, 2026
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
August 13, 2026
RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
July 1, 2026
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
October 7, 2025
RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort
November 5, 2024
RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study
August 3, 2024
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
December 5, 2023
RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis
July 29, 2022
RIBOMIC : Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia
April 19, 2022
RIBOMIC : Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration
March 23, 2022
RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration
December 28, 2021
RIBOMIC : Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
December 23, 2021
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
November 15, 2021
RIBOMIC : Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
November 15, 2021
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)
November 9, 2021
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting
September 30, 2021
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)
August 30, 2021
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)
August 4, 2021
RIBOMIC : Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients
July 12, 2021
RIBOMIC : Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium
May 28, 2021
Ribomic : Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)
May 25, 2021
RIBOMIC : Announces Publication of Research Paper on Aptamer Drug Discovery for Achondroplasia
May 21, 2021
RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR
May 21, 2021
RIBOMIC : Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia
May 21, 2021
Ribomic : Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31, 2020 (Based on Japanese GAAP)
February 24, 2021